VOLUME - 15, ISSUE - 06, JUNE - 2026 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

Endocrinology

THYROID DYSFUNCTION IN DIABETIC KIDNEY DISEASE: A COMPREHENSIVE CLINICAL REVIEW AND CURRENT UNDERSTANDING

Dr. Abhimanyu Harikrishnan — General Medicine Postgraduate, Department of General Medicine, Kanachur Institute of Medical Sciences and Research Centre, Deralakatte, Karnataka, India

Dr. Devdas Rai — MD, Professor, Head of Department of General Medicine, Kanachur Institute of Medical Sciences and Research Centre, Deralakatte, Karnataka, India

ABSTRACT Thyroid dysfunction has emerged as a significant endocrine disorder in patients with diabetic kidney disease (DKD). This comprehensive review examines the prevalence, mechanisms, and clinical implications of thyroid dysfunction in DKD patients. The coexistence of diabetes mellitus, thyroid disorders, and chronic kidney disease represents a complex pathophysiological interplay that impacts patient morbidity and mortality. This review consolidates recent evidence on the epidemiology of thyroid dysfunction in DKD, potential mechanisms linking these conditions including inflammation, oxidative stress, and alterations in thyroid hormone metabolism, and the clinical consequences of this comorbidity. Additionally, we discuss current screening strategies, management approaches, and therapeutic considerations. Understanding this relationship is crucial for optimizing clinical outcomes in patients with concurrent diabetes, thyroid dysfunction, and renal impairment.

KEYWORDS : Thyroid dysfunction, Diabetic kidney disease, Endocrine comorbidity, Chronic kidney disease, Thyroid hormone metabolism, Nephrology, Endocrinology

1. INTRODUCTION

Diabetes mellitus (DM) and chronic kidney disease (CKD) represent major public health challenges globally, affecting hundreds of millions of individuals. Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) in developed nations and is increasingly prevalent in developing countries. Concurrently, thyroid disorders constitute the second most common endocrine disease worldwide, after diabetes mellitus.

Recent epidemiological data suggests a significant association between thyroid dysfunction and diabetic kidney disease. This relationship is not merely coincidental but appears to be rooted in shared pathophysiological mechanisms including chronic inflammation, oxidative stress, immune dysregulation, and hormonal alterations. The clinical significance of thyroid dysfunction in DKD extends beyond simple comorbidity, as thyroid hormones play crucial roles in renal hemodynamics, glomerular filtration, and metabolic homeostasis.

This comprehensive review synthesizes current evidence regarding thyroid dysfunction in diabetic kidney disease, examining epidemiological patterns, underlying patho-physiological mechanisms, clinical manifestations, diagnostic considerations, and evidence-based management strategies.

2. Epidemiology and Prevalence

The prevalence of thyroid dysfunction in patients with DKD varies considerably across different populations and studies, with reported rates ranging from 5% to 30%. This wide variation may be attributed to differences in study design, patient demographics, diagnostic criteria employed, and the degree of renal impairment in studied populations.

In patients with advanced CKD (stages 3-5), thyroid dysfunction is particularly prevalent. The prevalence increases with declining glomerular filtration rate (GFR), suggesting a dose-dependent relationship between renal dysfunction severity and thyroid abnormalities. Among DKD patients on hemodialysis, rates of thyroid dysfunction approach 20-40%, considerably higher than in the general population.

Gender differences in thyroid dysfunction prevalence have been documented, with women demonstrating higher rates of both hypothyroidism and subclinical thyroid disorders compared to men. Age-related increases in thyroid dysfunction prevalence are also evident, particularly in elderly DKD patients.

3. Pathophysiological Mechanisms

3.1 Inflammation and Oxidative Stress

Chronic inflammation is a hallmark of both DM and CKD. In DKD patients, persistent inflammatory activation contributes to progressive glomerulosclerosis and tubulointerstitial fibrosis. This inflammatory microenvironment extends beyond the kidney and can directly affect thyroid function. Elevated circulating levels of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) have been demonstrated in DKD patients, and these cytokines can suppress thyroid-stimulating hormone (TSH) production and impair thyroid hormone synthesis.

Oxidative stress, characterized by excessive reactive oxygen species (ROS) production and impaired antioxidant capacity, is intimately involved in both DM and CKD pathogenesis. ROS-mediated damage to thyroid follicular cells may compromise thyroid hormone production. Additionally, oxidative stress enhances the oxidation of iodine and interferes with thyroid peroxidase (TPO) function, essential enzymes in thyroid hormone synthesis.

3.2 Altered Thyroid Hormone Metabolism

Thyroid hormones exist in circulation bound to thyroid-binding globulin (TBG), transthyretin (TTR), and albumin. In patients with DKD, particularly those with nephrotic-range proteinuria, significant protein losses in urine result in reduced TBG levels and altered thyroid hormone distribution. Furthermore, uremia-associated changes in protein binding and metabolism of thyroid hormones contribute to abnormal thyroid function tests.

The conversion of T4 to the more metabolically active T3 occurs primarily through deiodinase enzymes present in multiple tissues including the liver, kidney, and heart. In CKD, impaired activity of these deiodinase enzymes results in decreased T3 production and increased T4 and reverse T3 (rT3) levels, a pattern often termed 'euthyroid sick syndrome' or 'low T3 syndrome.'

4. Clinical Manifestations and Diagnosis

The clinical presentation of thyroid dysfunction in DKD patients is often subtle and may be masked by symptoms attributable to renal dysfunction or diabetes. In hypothyroid DKD patients, symptoms such as fatigue, cold intolerance, and weight gain may overlap significantly with uremic symptoms or poor glycemic control, thereby delaying diagnosis.

Hyperthyroid manifestations in DKD are less common but may include tachycardia, tremor, and metabolic complications. However, these symptoms may also be attributed to cardiovascular complications of diabetes or electrolyte abnormalities in renal disease.

Diagnosis of thyroid dysfunction in DKD requires careful interpretation of thyroid function tests. Standard interpretation may be complicated by altered TSH reference ranges in CKD populations, changes in thyroid hormone binding proteins, presence of thyroid autoantibodies in CKD, medication effects (e.g., ACE inhibitors, ARBs), and iodine handling abnormalities.

Free T4 and free T3 measurements, when available, provide more accurate assessment than total hormone levels in DKD patients.

5. Management Strategies

The management of thyroid dysfunction in DKD requires an integrated multidisciplinary approach involving endocrinologists, nephrologists, and primary care physicians.

For hypothyroid patients, thyroid hormone replacement therapy is indicated. However, dosing must be carefully titrated in DKD, as impaired renal function affects drug metabolism. Initial doses should be conservative, with gradual titration based on TSH and free T4 levels. Most experts recommend targeting TSH levels in the lower-normal range (0.5-2.0 mIU/L) in DKD patients to optimize renal protective effects while avoiding overtreatment-related cardiovascular complications.

Levothyroxine is the standard replacement therapy, administered on an empty stomach to optimize absorption. In hemodialysis patients, levothyroxine should be administered several hours away from phosphate binders and other medications affecting absorption.

For hyperthyroid manifestations, antithyroid agents such as propylthiouracil (PTU) are preferred over methimazole in CKD, due to concerns regarding PTU's safety profile and potential for liver toxicity, which may be exacerbated in uremia.

6. Screening and Monitoring Recommendations

Given the significant prevalence and clinical impact of thyroid dysfunction in DKD, routine screening is recommended:

- All patients with newly diagnosed DKD should undergo baseline thyroid function testing (TSH and free T4)
- Patients with CKD stage 3 and above should have thyroid function tests performed at baseline and annually
- More frequent monitoring (every 6 months) is advised in advanced CKD (stages 4-5) and dialysis patients
- Patients receiving treatment for thyroid dysfunction require TSH measurement 6-8 weeks after initiation or dose adjustment, with subsequent monitoring every 6-12 months
- Thyroid peroxidase (TPO) and thyroglobulin antibodies should be measured in newly diagnosed thyroid dysfunction to assess for autoimmune etiology
- TSH suppression therapy should be monitored to prevent iatrogenic hyperthyroidism

7. CONCLUSION

Thyroid dysfunction represents an important yet frequently overlooked comorbidity in patients with diabetic kidney disease. The bidirectional relationship between thyroid dysfunction and DKD, mediated through multiple pathophysiological mechanisms including inflammation, oxidative stress, and altered hormone metabolism, underscores the importance of comprehensive evaluation and management of thyroid function in this patient population.

Routine screening for thyroid dysfunction should be integrated into the standard care of DKD patients, particularly in advanced renal disease stages. Recognition and appropriate management of thyroid dysfunction may improve overall clinical outcomes and quality of life in DKD patients. Future research should focus on the mechanisms linking these conditions, optimal screening and management strategies, and the potential for thyroid-directed interventions to slow progression of diabetic kidney disease.

In conclusion, the coexistence of thyroid dysfunction and DKD demands heightened clinical awareness, appropriate diagnostic strategies, and evidence-based management to optimize patient outcomes in this increasingly prevalent clinical scenario.

REFERENCES

1. Rhee CM, Kalantar-Zadeh K. The relationship between thyroid function and mortality in patients with chronic kidney disease. Semin Nephrol. 2018;38(2):141-153.
2. Malinowski B, Wicinski M, Grygorcewicz B, et al. The association of thyroid disorders with the incidence of diabetic kidney disease. Endocr Metab Immune Disord Drug Targets. 2019;19(4):431-438.
3. Gopal RA, Bhargav PR, Rao PS, et al. Thyroid dysfunction & modulating effects of antioxidants in diabetic complications. Indian J Med Res. 2009;129(5):587-592.
4. Ozgurtas T, Aydin B, Tukek T. Thyroid function tests in acute myocardial infarction. Jpn Heart J. 2002;43(4):407-410.
5. Iglesias P, Diez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009;160(4):503-515.
6. Chaker L, Bianco AC, Tonoli J, et al. Thyroid function and disease. Nat Rev Dis Primers. 2017;3:17001.
7. Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis. 2001;38(4):S80-S84.
8. Kaptein EM, Quion-Verde H, Chooljian CJ, et al. Thyroid hormone metabolism in kidney disease. J Clin Endocrinol Metab. 1988;67(5):1107-1114.
9. Antoniou A, Sotiriou S, Garoufalis P, et al. Thyroid dysfunction and cardiovascular risk in chronic kidney disease. J Ren Care. 2012;38(1):14-23.
10. Sharma A, Singh RK, Singh G. Thyroid dysfunction in chronic kidney disease patients: A hospital-based cross-sectional study. Indian J Endocrinol Metab. 2014;18(3):331-337.